TinyGemsBreaks Archive - Page 114 of 148

MondayNov 28, 2022 12:29 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) K1 Technology Deployed for Transit System Client

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, has announced that an existing California-based transit client signed a contract to upgrade 97 of its parking lot emergency call boxes with the Knightscope K1 Retrofit Kits. The announcement reads, “In 2022, this client averaged approximately 136,000 weekday passengers. Knightscope’s K1 emergency blue light communication devices serve to deter potential negative activities using cellular and satellite communications with solar power to passengers for additional safety in remote locations. The newer, more advanced wireless systems will save the client money on both infrastructure and hardware costs, while improving reliability on a…

MondayNov 28, 2022 11:10 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces Q3 2022 Financial Results

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, released its financial and operating results for the third quarter and nine months ended Sept. 30, 2022. Among the highlights, the company reported 414% year-over-year and 510% year-over-year increases in revenue for the three-month period and nine-month period ended Sept. 30, 2022. In addition, Flora achieved a 703% year-over-year increase in gross profit for the three-month period ended Sept. 30, 2022. The company will discuss these results in its earnings call at 4:30 p.m. ET today, as detailed in the press release. “The third…

WednesdayNov 23, 2022 3:26 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at…

WednesdayNov 23, 2022 2:17 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Bridging Gap Between Lidar Concept and Deployment with NVIDIA DRIVE Sim(TM)

Cepton (NASDAQ: CPTN) recently teamed up with NVIDIA to add its lidars into NVIDIA DRIVE Sim(TM) – an end-to-end simulation platform for large-scale, accurate multi-sensor simulation that supports autonomous driving development and validation from concept to deployment. “With this collaboration, Cepton seeks to accelerate the development of lidar solutions for assisted and autonomous driving for global consumers. NVIDIA DRIVE Sim simulations enable automakers and developers to work with Cepton’s lidar models in a virtual environment to identify suitable Cepton lidar sensors for specific application needs and integrate them with other sensor technologies, such as camera and radar. They can prototype…

TuesdayNov 22, 2022 10:45 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, which were issued at a purchase price of $3.30 per share (or prefunded warrant in lieu thereof); the shares were priced at-the-market under NASDAQ rules. The announcement also noted that InMed issued unregistered preferred investment options to the investors in the offering to purchase up to 3,272,733 common shares. The offering resulted in approximately $6 million in gross proceeds for…

TuesdayNov 22, 2022 10:30 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Releases Q3 2022 Financial Report

Freight Technologies (NASDAQ: FRGT), a technology company based on its custom-developed Fr8App platform, which is powered by AI and machine learning and which offers a real-time portal for B2B cross-border shipping and domestic shipping within the United States-Mexico-Canada (“NAFTA”) region, is reporting on its third-quarter 2022 revenue for the period ended Sept. 30, 2022. According to the report, the company showed revenue growth of 38% over the same period last year, reporting revenue of $7.7 million for this quarter compared to $5.6 million for Q3 2021. The company also announced an adjustment in full-year 2022 revenue guidance, increasing it to…

MondayNov 21, 2022 2:25 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) CEO Discusses Vast Potential of Autonomous Technology in ‘Get Authentic’ Interview

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, was featured in Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. The company’s chairman and CEO William Santana Li joined the broadcast, hosted by NFL veteran and best-selling author Marques Ogden, to discuss Knightscope’s technology and how it is aiding the company in disrupting the $500 billion security industry. Li said in the interview, “We have this crazy mission at Knightscope to make the U.S. the safest country in the world. We…

MondayNov 21, 2022 12:47 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Focus on Dementia and Diabetes Featured in New Interview

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in an interview produced by PCG Digital Holdings LLC and published on NewMediaWire. John Docherty, Lexaria’s president and head of research, discussed the company’s efforts to investigate the potential therapeutic utility of its proprietary DehydraTECH(TM)-CBD against dementia and diabetes, two of the world’s largest public health crises. Lexaria recently demonstrated DehydraTECH-CBD’s exceptional safety and tolerability in a human hypertension study, as well as statistically significant lowering of blood pressure over multiple weeks (something that previous studies by others have failed to evidence). Strong connections exist between…

MondayNov 21, 2022 11:32 am

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Schedules Q3 2022 Earnings Call

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that it will host its third quarter 2022 earnings call via webcast at 4:30 p.m. ET on Monday, Nov. 28. During the webcast, Flora management will deliver financial and operational results for the third quarter ended Sept. 30, 2022, and provide updates on the company’s commercial wholesale operations, house of brands and life sciences division strategies. Following the presentation, Flora management will open the call to analysts, media and investors in a Q&A format. Interested parties should visit https://ibn.fm/j1zip to register for…

FridayNov 18, 2022 12:29 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks